乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展

国际肿瘤学杂志››2024,Vol. 51››Issue (3): 166-169.doi:10.3760/cma.j.cn371439-20231130-00026

乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展

张丽丽¹, 谭茹², 房雪利¹, 杨宇¹, 桑铮¹, 李宝生¹()

¹betway必威登陆网址附属肿瘤医院放疗科，济南 250117
²betway必威登陆网址附属省立医院影像科，济南 250021

收稿日期:2023-11-30修回日期:2023-12-26出版日期:2024-03-08发布日期:2024-04-10
通讯作者:李宝生，Email： baoshli1963@163.com

Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinomain situof the breast

Zhang Lili¹, Tan Ru², Fang Xueli¹, Yang Yu¹, Sang Zheng¹, Li Baosheng¹()

¹Department of Radiation Oncology， Cancer Hospital Affiliated to Shandong First Medical University， Jinan 250117， China
²Department of Imaging， Shandong Provincial Hospital Affiliated to Shandong First Medical University， Jinan 250021， China

Received:2023-11-30Revised:2023-12-26Online:2024-03-08Published:2024-04-10
Contact:Li Baosheng， Email： baoshli1963@163.com

摘要/Abstract

摘要：

乳腺导管原位癌（DCIS）X线最常见的表现为无症状钙化，MRI最常见的表现为非肿块性强化，超声主要表现为不规则的低回声富血供肿块，不伴后方特征。空芯针穿刺活检术是术前诊断DCIS的常用方式，由于穿刺针类型及取样大小的差异，病变存在一定程度的病理学升级。近年来，对于DCIS的诊断和治疗一直存在争议。随着乳腺疾病诊断技术的发展，数字乳腺断层合成摄影、人工智能和影像组学的进展均有望帮助管理DCIS和解决过度诊断等问题。

关键词:癌,导管内,非浸润性,影像学诊断,病理学升级

Abstract:

Ductal carcinomain situof the breast （DCIS） most commonly manifests as asymptomatic calcifications at mammography. The most common manifestation of MRI is nonmass enhancement. The ultrasound mainly presents as a hypoechoic irregular hypervascular mass without posterior features. Core-needle biopsy is a commonly used method for preoperative diagnosis of DCIS. Due to differences in needle type and sample size， there is a certain degree of pathological upgrading of the lesion. In recent years， there has been controversy over the diagnosis and treatment of DCIS. With the development of breast disease diagnostic technology， advances in digital breast tomography， artificial intelligence， and radiomics are expected to help DCIS management and address issues such as overdiagnosis.

Key words:Carcinoma,intraductal,noninfiltrating,Imaging diagnosis,Pathology upgrade

张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.

Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinomain situof the breast[J]. Journal of International Oncology, 2024, 51(3): 166-169.

参考文献25

[1]	Wilson GM, Dinh P, Pathmanathan N, et al. Ductal carcinoma in situ: molecular changes accompanying disease progression[J].J Mammary Gland Biol Neoplasia,2022,27(1): 101-131. DOI:10.1007/s10911-022-09517-7.
[2]	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J].CA Cancer J Clin,2022,72(6): 524-541. DOI:10.3322/caac.21754.
[3]	Salvatorelli L, Puzzo L, Vecchio GM, et al. Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors[J].Cancers (Basel),2020,12(3): 609. DOI:10.3390/cancers12030609.
[4]	Grimm LJ, Rahbar H, Abdelmalak M, et al. Ductal carcinoma in situ: state-of-the-art review[J].Radiology,2022,302(2): 246-255. DOI:10.1148/radiol.211839.
[5]	D'Orsi CJ. Imaging for the diagnosis and management of ductal carcinoma in situ[J].J Natl Cancer Inst Monogr,2010,2010(41): 214-217. DOI:10.1093/jncimonographs/lgq037.
[6]	Kim G, Mikhael PG, Oseni TO, et al. Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade[J].Eur Radiol,2020,30(11): 6089-6098. DOI:10.1007/s00330-020-07021-2.
[7]	Chou SS, Romanoff J, Lehman CD, et al. Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial)[J].Radiology,2021,301(1): 66-77. DOI:10.1148/radiol.2021204743.
[8]	Bragg A, Candelaria R, Adrada B, et al. Imaging of noncalcified ductal carcinoma in situ[J].J Clin Imaging Sci,2021,11: 34. DOI:10.25259/JCIS_48_2021. pmid:34221643
[9]	Shehata M, Grimm L, Ballantyne N, et al. Ductal carcinoma in situ: current concepts in biology, imaging, and treatment[J].J Breast Imaging,2019,1(3): 166-176. DOI:10.1093/jbi/wbz039. pmid:31538141
[10]	Amornsiripanitch N, Lam DL, Rahbar H. Advances in breast MRI in the setting of ductal carcinoma in situ[J].Semin Roentgenol,2018,53(4): 261-269. DOI:10.1053/j.ro.2018.08.006. pmid:30449344
[11]	Oda G, Nakagawa T, Ogawa A, et al. Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS[J].Mol Clin Oncol,2020,13(1): 67-72. DOI:10.3892/mco.2020.2036.
[12]	Greenwood HI, Wilmes LJ, Kelil T, et al. Role of breast MRI in the evaluation and detection of DCIS: opportunities and challenges[J].J Magn Reson Imaging,2020,52(3): 697-709. DOI:10.1002/jmri.26985. pmid:31746088
[13]	van Seijen M, Lips EH, Thompson AM, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question[J].Br J Cancer,2019,121(4): 285-292. DOI:10.1038/s41416-019-0478-6.
[14]	Schmitz RSJM, Wilthagen EA, van Duijnhoven F, et al. Prediction models and decision aids for women with ductal carcinoma in situ: a systematic literature review[J].Cancers (Basel),2022,14(13): 3259. DOI:10.3390/cancers14133259.
[15]	Moon HJ, Kim EK, Kim MJ, et al. Comparison of clinical and pathologic characteristics of ductal carcinoma in situ detected on mammography versus ultrasound only in asymptomatic patients[J].Ultrasound Med Biol,2019,45(1): 68-77. DOI:10.1016/j.ultrasmedbio.2018.09.003. pmid:30322671
[16]	Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer[J].Radiology,2011,260(1): 119-128. DOI:10.1148/radiol.11102368. pmid:21493791
[17]	Nicosia L, Bozzini AC, Penco S, et al. A model to predict upsta-ging to invasive carcinoma in patients preoperatively diagnosed with low-grade ductal carcinoma in situ of the breast[J].Cancers (Basel),2022,14(2): 370. DOI:10.3390/cancers14020370.
[18]	Chong A, Weinstein SP, McDonald ES, et al. Digital breast tomosynthesis: concepts and clinical practice[J].Radiology,2019,292(1): 1-14. DOI:10.1148/radiol.2019180760. pmid:31084476
[19]	范文文, 欧阳汉, 周纯武, 等. 数字乳腺断层成像与磁共振成像对乳腺肿瘤的诊断价值[J].放射学实践,2020,35(3): 360-364. DOI:10.13609/j.cnki.1000-0313.2020.03.020.
[20]	杨彩仙, 赵宏光, 刘慧, 等. 乳腺癌数字化X线三维断层摄影肿块边缘征象及其与病理学指标的相关性[J].肿瘤研究与临床,2019,31(1): 16-21. DOI:10.3760/cma.j.issn.1006-9801.2019.01.004.
[21]	Park KW, Kim SW, Han H, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer[J].NPJ Breast Cancer,2022,8(1): 8. DOI:10.1038/s41523-021-00364-z. pmid:35031626
[22]	Shi B, Grimm LJ, Mazurowski MA, et al. Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features[J].J Am Coll Radiol,2018,15(3 Pt B): 527-534. DOI:10.1016/j.jacr.2017.11.036. pmid:29398498
[23]	Zhu Z, Harowicz M, Zhang J, et al. Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ[J].Comput Biol Med,2019,115: 103498. DOI:10.1016/j.compbiomed.2019.103498.
[24]	Hou R, Grimm LJ, Mazurowski MA, et al. Prediction of upstaging in ductal carcinoma in situ based on mammographic radiomic features[J].Radiology,2022,303(1): 54-62. DOI:10.1148/radiol.210407.
[25]	Lee HJ, Park JH, Nguyen AT, et al. Prediction of the histologic upgrade of ductal carcinoma in situ using a combined radiomics and machine learning approach based on breast dynamic contrast-enhanced magnetic resonance imaging[J].Front Oncol,2022,12: 1032809. DOI:10.3389/fonc.2022.1032809.